Diabetes Management Issues for Patients With Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
IN BRIEF Chronic kidney disease (CKD) is common and can be found in up to 23% of patients with diabetes. The recommended hemoglobin A1c goal for these patients is also < 7.0%. Medication therapy for diabetes may require dose adjustments or may be contraindicated in patients with CKD. Assessment and management of comorbid diseases, including hypertension, hyperlipidemia,anemia, hyperphosphatemia, and hyperparathyroidism, is important in the care of patients with diabetes and CKD. Multidisciplinary care may provide the optimal system for maximizing care of these complex patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
Barnett, A. H., Bain, S. C., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J., & Mustonen, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042274 · Cited by 910
Kramer, H. J. (2003) · JAMA · doi:10.1001/jama.289.24.3273 · Cited by 618
Kasiske, B., Lakatua, J., Ma, J., & Louis, T. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9631839 · Cited by 408
Assessing Glycemia in Diabetes Using Self-monitoring Blood Glucose and Hemoglobin A 1c
Saudek, C. D., Derr, R. L., & Kalyani, R. R. (2006) · JAMA · doi:10.1001/jama.295.14.1688 · Cited by 373
Hypoglycemia in patients with type 2 diabetes mellitus
Miller, C. D., Phillips, L. S., Ziemer, D. C., Gallina, D. L., Cook, C. B., & El-Kebbi, I. M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1653 · Cited by 341
Rahman, M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.936 · Cited by 340
Snyder, R. W., & Berns, J. S. (2004) · Seminars in Dialysis · doi:10.1111/j.0894-0959.2004.17346.x · Cited by 215
Effect of pravastatin in people with diabetes and chronic kidney disease
Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005070779 · Cited by 159
Cited by
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
Yale, J. ‐., Bakris, G., Cariou, B., Yue, D., David‐Neto, E., Xi, L., Figueroa, K., Wajs, E., Usiskin, K., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12090 · Cited by 487
Yale, J. ‐., Bakris, G., Cariou, B., Nieto, J., David‐Neto, E., Yue, D., Wajs, E., Figueroa, K., Jiang, J., Law, G., et al. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12348 · Cited by 273
Fioretto, P., Del Prato, S., Buse, J. B., Goldenberg, R., Giorgino, F., Reyner, D., Langkilde, A. M., Sjöström, C. D., Sartipy, P., & On Behalf of the DERIVE Study Investigators (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13413 · Cited by 195
Incidence of Remission in Adults With Type 2 Diabetes: The Diabetes & Aging Study
Karter, A. J., Nundy, S., Parker, M. M., Moffet, H. H., & Huang, E. S. (2014) · Diabetes Care · doi:10.2337/dc14-0874 · Cited by 132
“Because insulin is normally metabolized by the kidney (32), worsening renal function can lead to improved glycemic control (33); however, this typ-”
BackgroundInsulin Degludec: Pharmacokinetics in Patients with Renal Impairment
Kiss, I., Arold, G., Roepstorff, C., Bøttcher, S. G., Klim, S., & Haahr, H. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0113-2 · Cited by 75
“In addition, deterioration of renal function can lead to increased exposure to insulin therapy, potentially increasing the risk of hypoglycemia and hampering effective diabetes management in these patients [1].”
Background
Metadata
- Authors
- Cavanaugh, K. L.
- Venue
- Clinical Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-07-01
- Volume
- 25
- Issue
- 3
- Pages
- 90-97
- ISSN
- 0891-8929 (ISSN-L)
- 1945-4953
- OpenAlex
- W2122808146
- Cited by
- 82
- References
- 13
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.